Business
Viking Therapeutics shares rise after Madrigal shares positive data on liver disease drug
Shares of Viking Therapeutics Inc.
VKTX,
saw a 55% increase in premarketing on Monday after a company was also developing a beta-selective thyroid hormone receptor agonist to treat non-alcoholic steatohepatitis (NASH) and cirrhosis. has published positive data in the late stages. Madrigal pharmaceutical company
MDGL,
said Monday it is aiming to gain rapid approval in the United States for its drug. The “treatment candidate” is currently in a Phase 2b clinical trial. The company’s shares are down 24.7% year-to-date, while the broader S&P 500 index
SPX,
fell 19.1%.